Polianta LTD Summit Therapeutics Inc. Transaction History
Polianta LTD
- $232 Million
- Q2 2025
A detailed history of Polianta LTD transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Polianta LTD holds 60,600 shares of SMMT stock, worth $1.32 Million. This represents 0.56% of its overall portfolio holdings.
Number of Shares
60,600
Previous 60,600
-0.0%
Holding current value
$1.32 Million
Previous $1.17 Million
10.36%
% of portfolio
0.56%
Previous 0.56%
Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
263Shares Held
90.3MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$733 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$189 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$172 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$87.4 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$84.9 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.38B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...